Japanese Pharma Companies Speed Up Mergers And Acquisitions In Growing Biopharmaceutical Arena
This article was originally published in PharmAsia News
Executive Summary
Major Japanese pharmaceutical companies have been in an uphill battle to develop new drugs, and as the biopharmaceutical industry captures attention, they are increasingly turning to mergers and acquisitions overseas with leading international biopharmaceutical companies. Eisai bought an American biopharma venture for ¥430 billion. Last year, Takeda set up an antibody research facility in San Francisco, where many of America's biopharma companies are concentrated. On Feb. 4, Takeda announced a buyout of Amgen's wholly-owned business unit in Japan. Through the purchase, Takeda obtained licensing rights for the sole development and marketing of 13 new drugs in Japan, including cancer drug AMG706 (motesanib) and other antibody drugs. It is expected that the buyout will speed up Takeda's presence in this growing area. (Click for more-Japanese language
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.